Approximately 11,960 people will be diagnosed with acute myeloid leukemia (AML) in 2005, and 9,000 patients will die of the disease. As the population ages, the incidence of AML, along with myelodysplasia, appears to be rising. Equally disturbing is the increasing incidence of treatment-related myelodysplasia and leukemia in survivors of tumors of childhood and young adulthood such as Hodgkin's disease, sarcomas, breast and testicular cancers, and lymphomas. Recent large clinical trials have highlighted the need for new, innovative strategies because outcomes for AML patients, particularly older patients, have not substantially changed in the past 3 decades.
For the most recent version of the guidelines, please visit NCCN.org
If the inline PDF is not rendering correctly, you can download the PDF file here.
Since 1898, Roswell Park Cancer Institute (RPCI), America's first cancer center, has forged an exemplary reputation based on the combined strength of its basic/translational research, multidisciplinary oncology teams, educational programs, and compassionate staff. A seamless interface of scientific inquiry and clinical application, and an aggressive clinical trials program, afford patients access to promising breakthroughs in cancer diagnostics, technology, and treatments.
Since 1998, 60% of RPCI's 25-acre campus has undergone major renovation and expansion. A world-class Center for Genetics and Pharmacology will open in spring 2006.
RPCI ranks among the nation's top 1% of cancer centers and teaching hospitals for patient satisfaction with physician services and overall care.
David C. Hohn, MD (second photo on cover), joined Roswell Park Cancer Institute as President and CEO in January of 1997. Dr. Hohn oversees operations of the hospital, research facilities, and the education department. Dr. Hohn also serves as Chairman of the Board for the National Comprehensive Cancer Network.